Mallinckrodt PLC (MNK) Director David R. Carlucci Purchases 10,000 Shares of Stock
Mallinckrodt PLC (NYSE:MNK) Director David R. Carlucci purchased 10,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were bought at an average cost of $21.83 per share, with a total value of $218,300.00. Following the acquisition, the director now directly owns 26,020 shares of the company’s stock, valued at approximately $568,016.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Mallinckrodt PLC (NYSE:MNK) opened at $21.90 on Tuesday. Mallinckrodt PLC has a 52-week low of $19.00 and a 52-week high of $68.12. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.05 and a current ratio of 1.38. The stock has a market capitalization of $2,067.31, a P/E ratio of 2.94, a price-to-earnings-growth ratio of 0.33 and a beta of 1.46.
Mallinckrodt PLC (NYSE:MNK) last issued its quarterly earnings data on Tuesday, November 7th. The company reported $1.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.17. Mallinckrodt PLC had a return on equity of 14.79% and a net margin of 11.43%. The business had revenue of $793.90 million for the quarter, compared to the consensus estimate of $808.93 million. During the same period in the prior year, the business posted $2.04 earnings per share. The company’s quarterly revenue was down 10.5% compared to the same quarter last year. equities research analysts predict that Mallinckrodt PLC will post 7.23 EPS for the current year.
TRADEMARK VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/14/mallinckrodt-plc-mnk-director-david-r-carlucci-purchases-10000-shares-of-stock.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. raised its holdings in shares of Mallinckrodt PLC by 15.4% in the second quarter. Alliancebernstein L.P. now owns 3,348,807 shares of the company’s stock worth $150,060,000 after buying an additional 448,011 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Mallinckrodt PLC by 16.7% in the third quarter. Dimensional Fund Advisors LP now owns 2,522,330 shares of the company’s stock worth $94,255,000 after buying an additional 360,516 shares during the period. HealthCor Management L.P. purchased a new stake in shares of Mallinckrodt PLC in the second quarter worth approximately $107,649,000. Ameriprise Financial Inc. raised its holdings in shares of Mallinckrodt PLC by 2.6% in the third quarter. Ameriprise Financial Inc. now owns 1,987,196 shares of the company’s stock worth $74,260,000 after buying an additional 49,752 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Mallinckrodt PLC by 6,828.1% in the second quarter. Janus Henderson Group PLC now owns 1,396,780 shares of the company’s stock worth $62,590,000 after buying an additional 1,376,619 shares during the period. Hedge funds and other institutional investors own 98.83% of the company’s stock.
Several analysts have issued reports on MNK shares. Zacks Investment Research lowered Mallinckrodt PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. UBS AG reissued a “buy” rating and set a $70.00 price target on shares of Mallinckrodt PLC in a report on Wednesday, September 6th. Cantor Fitzgerald reissued a “buy” rating and set a $52.00 price target on shares of Mallinckrodt PLC in a report on Thursday, November 2nd. BidaskClub raised Mallinckrodt PLC from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Finally, Deutsche Bank AG reissued a “buy” rating and set a $45.00 price target (down previously from $56.00) on shares of Mallinckrodt PLC in a report on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. Mallinckrodt PLC currently has an average rating of “Hold” and a consensus target price of $48.14.
About Mallinckrodt PLC
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Stock Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related stocks with our FREE daily email newsletter.